AprilBio KRX:397030KOSDAQ
에이프릴바이오 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days1
Articles tracked0since Sep 11
In Q2 2026, AprilBio reported an operating loss of ₩2.9bn. AprilBio (에이프릴바이오) appeared in 0 Korean news articles and 1 DART filing over the past seven days.
Filing signals 4 quarters of losses Screener
AprilBio quarterly results separate, KRW
| Quarter | Operating profit | Net income |
|---|---|---|
| Q2 2026 | −₩2.9bn | −₩2.0bn |
| Q1 2026 | −₩2.2bn | ₩201m |
| Q4 2025 derived | −₩2.0bn | −₩2.3bn |
| Q3 2025 | −₩2.5bn | −₩5.0bn |
| Q2 2025 | −₩2.7bn | −₩3.1bn |
| Q1 2025 | −₩110m | ₩594m |
| Q4 2024 derived | ₩3.7bn | ₩6.6bn |
| Q3 2024 | −₩2.4bn | −₩3.1bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
AprilBio top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest AprilBio news Korean headlines
No articles yet.